Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback